AVImark vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Widely deployed on-premise veterinary PMS now owned by Covetrus and integrated with IDEXX reference labs. Large installed base of independent US small-animal practices that adopted AVImark as the de facto standard before cloud alternatives;
About
AVImark is a veterinary practice management software system that has been widely deployed in independent veterinary practices across the United States for decades, and is currently owned by Covetrus—the animal health technology and distribution company formed from the combination of Henry Schein Animal Health and Vets First Choice, which was subsequently acquired by IDEXX Laboratories. AVImark's strength lies in its deep penetration of the independent small-animal practice market, where it became the de facto standard system for many practices that adopted practice management software in the 1990s and 2000s. The software provides scheduling, medical records, invoicing, inventory management, and client communication in an on-premise Windows-based system that has been continuously developed and supported through multiple ownership transitions.\n\nAVImark's integration with IDEXX's reference laboratory and diagnostic services is a significant feature of the current product, allowing practices to send laboratory orders electronically and receive results directly within the AVImark patient record. This IDEXX connectivity is particularly valuable for practices that are already IDEXX lab customers and want to reduce manual result transcription. Covetrus has also integrated AVImark with its online pharmacy and prescription management services, creating a connected ecosystem that links practice management, diagnostics, and medication dispensing for AVImark-using clinics.\n\nAVImark faces competitive pressure from cloud-native veterinary practice management systems including Shepherd, ezyVet, and Digitail that offer more modern user experiences, mobile accessibility, and frequent feature updates without requiring on-premise hardware. Covetrus has been investing in a cloud migration path for AVImark customers while also offering its newer Pulse platform as a cloud-native alternative for practices ready to move off legacy on-premise systems. The installed base of AVImark users represents a significant asset for Covetrus but also a long-term migration and retention challenge as the industry shifts toward cloud deployment.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.